文献速递艾滋病与性传播感染

间歇两药抗逆转录病毒治疗在经治HIV感染者中维持长期病毒抑制

Intermittent two-drug antiretroviral therapies maintain long-term viral suppression in real life in highly experienced HIV-infected patients.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

这项单中心观察性研究纳入85例病毒抑制的经治HIV感染者,评估每周4-5天间歇两药方案在48周和96周的病毒学失败率。结果显示48周病毒学成功率98.8%(95%CI 93.6-100),96周95.3%(95%CI 88.4-98.7),CD4/CD8比值小幅升高(P=0.009),提示该策略有潜力但需更大规模随机研究验证。

要点

  • 间歇两药方案在经治HIV感染者中48周病毒学成功率98.8%,96周95.3%。
  • 4例病毒学失败中3例恢复每日服药后重新抑制,1例出现M184V突变。
  • 研究期间CD4/CD8比值小幅升高(P=0.009),CD4计数和残余病毒血症无显著变化。

核心结论

  • 间歇两药方案在高度经治HIV感染者中可维持较高病毒学成功率,但需更大规模前瞻性随机研究评估。

研究设计与样本

  • 单中心观察性研究,纳入2016年1月1日至2019年6月30日启动间歇两药方案的全部患者,共85例。
  • 主要结局为48周和96周的病毒学失败率,定义为确认血浆病毒载量≥50 copies/mL或单次≥50 copies/mL后调整抗逆转录病毒治疗。

主要发现

  • 85例中67/85(79%)为男性,中位年龄57岁(IQR 50-63),CD4最低值233 cells/mm3(110-327),抗逆转录病毒治疗时长21年(13-24),病毒抑制时长6.5年(3.7-10.8),CD4计数658 cells/mm3(519-867)。
  • 间歇两药方案构成:整合酶链转移抑制剂(INSTI)/非核苷类逆转录酶抑制剂(NNRTI)58%,INSTI/核苷类逆转录酶抑制剂(NRTI)13%,两种NRTI 11%,蛋白酶抑制剂(PI)/NRTI 7%,其他组合11%。
  • 中位随访90周(IQR 64-111),共发生4例病毒学失败,48周病毒学成功率98.8%(95%CI 93.6-100),96周95.3%(95%CI 88.4-98.7)。
  • 恢复同一两药方案每日服药后3例重新抑制,1例出现M184V突变并调整治疗。
  • CD4计数和残余病毒血症率无显著变化,CD4/CD8比值在研究期间小幅升高(P=0.009)。

临床怎么用

  • 在病毒抑制的经治HIV感染者中,间歇两药方案可作为潜在选择,但需密切监测病毒载量。
  • 出现病毒学失败时可尝试恢复每日服药,但需警惕耐药突变(如M184V)并及时调整方案。

局限性

  • 单中心观察性研究,样本量85例,结果需更大规模前瞻性随机研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess in real life whether two-drug regimens (2-DRs) given 4-5 days a week in virally suppressed patients can maintain viral suppression over 48 and 96 weeks. METHODS: This observational single-centre study enrolled all patients who initiated an intermittent 2-DR between 01/01/2016 and 30/06/2019. The primary outcome was the rate of virological failure (VF), defined as confirmed plasma viral load (pVL) ≥50 copies/mL or single pVL ≥50 copies/mL followed by ART change at week 48 (W48) and W96. Secondary outcomes were the 2-DR intermittent strategy success rate (pVL <50 copies/mL with no ART change), change in CD4 count, CD4/CD8 ratio and rate of residual viraemia. RESULTS: Eighty-five patients were included; 67/85 (79%) were men, median age = 57 years (IQR = 50-63), CD4 nadir = 233 cells/mm3 (110-327), ART duration = 21 years (13-24), duration of virological suppression = 6.5 years (3.7-10.8) and CD4 count = 658 cells/mm3 (519-867). Intermittent 2-DRs consisted of integrase strand transfer inhibitor (INSTI)/NNRTI (58%), INSTI/NRTI (13%), two NRTIs (11%), PI/NRTI (7%) and other combinations (11%). The median follow-up was 90 weeks (IQR = 64-111). Overall, four VFs occurred, leading to a virological success rate of 98.8% (95% CI = 93.6-100) at W48 and 95.3% (95% CI = 88.4-98.7) at W96. Resuming the same 2-DR 7 days a week led to viral resuppression in three patients, whereas the M184V mutation emerged in one patient, leading to ART modification. There was no significant change in the CD4 count or residual viraemia rate, but a small increase in the CD4/CD8 ratio (P = 0.009) occurred over the study period. CONCLUSIONS: This observational study shows the potential for intermittent 2-DRs to maintain a high virological success rate, which should be assessed in larger prospective randomized studies.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Palich R, Abdi B, Wirden M, et al. Intermittent two-drug antiretroviral therapies maintain long-term viral suppression in real life in highly experienced HIV-infected patients. J Antimicrob Chemother. 2021. PMID: 33855355. doi:10.1093/jac/dkab108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。